BIOVAIL SHIFTS GEARS IN RESPONSE TO GENERIC COMPETITION

Biovail Corp., faced with looming generic competition for its most profitable drug, will speed the development of other products, seek acquisitions and cancel a planned spinoff of a portfolio of older drugs.
Canada.com